Free Trial
NASDAQ:SGMO

Sangamo Therapeutics Q2 2025 Earnings Report

Sangamo Therapeutics logo
$0.56 +0.02 (+4.56%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$0.56 0.00 (-0.28%)
As of 08/1/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sangamo Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.07
Beat/Miss
N/A
One Year Ago EPS
N/A

Sangamo Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$31.68 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sangamo Therapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, August 7, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Sangamo Therapeutics Earnings Headlines

Alex’s “Next Magnificent Seven” stocks
The original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Magnificent Seven—seven stocks he believes could deliver similar gains in under six years. His full breakdown is now live.
See More Sangamo Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sangamo Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sangamo Therapeutics and other key companies, straight to your email.

About Sangamo Therapeutics

Sangamo Therapeutics (NASDAQ:SGMO), a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.

View Sangamo Therapeutics Profile

More Earnings Resources from MarketBeat